Advanced in Stomach Cancer

Shen Lin

State Key Laboratory Of Medicinal Chemical Biology, Tianjin Key Laboratory Of Biosensing And Molecular Recognition, 
Changhongjie, CN 
Advanced in Stomach Cancer
State Key Laboratory Of Medicinal Chemical Biology, Tianjin Key Laboratory Of Biosensing And Molecular Recognition, 
Changhongjie, CN 
OverviewLocationsClinical Research

Overview

Shen Lin practices in Changhongjie, China. Mr. Lin is rated as an Advanced expert by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Gastroesophageal Junction Cancer, Gastrointestinal Stromal Tumor, Stomach Cancer, and Neuroendocrine Tumor.

His clinical research consists of co-authoring 12 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 2 clinical trials in the study of Stomach Cancer.

Gender
Male

Locations

State Key Laboratory Of Medicinal Chemical Biology, Tianjin Key Laboratory Of Biosensing And Molecular Recognition, Changhongjie, 300071, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Real-world Study to Explore and Evaluate Individualized Targeted Agents for Patients of Digestive Cancers Based on Molecular Characteristics After Standard Therapy Failure in China
A Real-world Study to Explore and Evaluate Individualized Targeted Agents for Patients of Digestive Cancers Based on Molecular Characteristics After Standard Therapy Failure in China
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2024
Intervention Type: Drug
Study Phase: Not Applicable
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers - An International, Multi-Center, Double Blind, Randomized Placebo Controlled Phase III Trial
Enrollment Status: Unknown
Publish Date: February 02, 2024
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma
Enrollment Status: Terminated
Publish Date: January 22, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
A Randomized, Multicenter, Controlled Phase III Study to Compare Perioperative Chemotherapy of Oxaliplatin Combined With S-1(SOX) Versus SOX or Oxaliplatin With Capecitabine (XELOX) as Post-operative Chemotherapy in Locally Advanced Gastric Adenocarcinoma With D2 Dissection
Enrollment Status: Unknown
Publish Date: September 17, 2019
Intervention Type: Drug
Study Drugs: Oxaliplatin Capecitabine, Oxaliplatin S-1
Study Phase: Phase 3
Phase Ib Study of Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Neuroendocrine Tumors Following Failure of First-Line
Phase Ib Study of Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Neuroendocrine Tumors Following Failure of First-Line
Enrollment Status: Completed
Publish Date: June 21, 2019
Intervention Type: Biological
Study Phase: Phase 1
View 4 Less Clinical Trials

12 Total Publications

Nanozyme-Triggered Cascade Reactions from Cup-Shaped Nanomotors Promote Active Cellular Targeting.
Nanozyme-Triggered Cascade Reactions from Cup-Shaped Nanomotors Promote Active Cellular Targeting.
Journal: Research (Washington, D.C.)
Published: March 13, 2022

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lin's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile